Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease

By sjmartinez • November 14, 2024

Benitez CM, Sahlstedt H, Sonni I, Brynolfsson J, Berenji GR, Juarez JE, Kane N, Tsai S, Rettig M, Nickols NG, Duriseti S. Treatment Response Assessment According to Updated PROMISE Criteria in Patients with Metastatic Prostate Cancer Using an Automated Imaging Platform for Identification, Measurement, and Temporal Tracking of Disease. Eur Urol Oncol. 2024 Nov 8:S2588-9311(24)00240-2. doi: 10.1016/j.euo.2024.10.011. Epub ahead of print. PMID: 39521638.

Tags: Artificial intelligence, Automated, Hematology/Oncology, Positron emission tomography, prostate-specific membrane antigen, Publications, Veterans Administration

Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer

Sayar E, Richards HM, Gulati R, Patel RA, Hanratty B, Lee HJ, Coleman I, Mustafi P, Ding CC, Chen WS, Quigley D, Setty M, Lang[...]

Global prevalence of FGFR2b protein overexpression in advanced gastric cancer and gastroesophageal junction cancers: pooled analysis of two bemarituzumab phase III studies

Maron SB, Xu RH, Wainberg ZA, Rha SY, Zhang Y, Pietrantonio F, Oliveira SCS, Li Y, Chen MH, Korphaisarn K, Elimova E, Calderon CA, Herpe[...]

Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249

Kuroki LM, Enserro DM, Lankes HA, Strickland KC, Previs R, Clements A, Powell MA, Klopp A, Ratner E, DiSilvestro P, Cosgrove C, Cantuaria GH, Spirtos[...]